Current Oncology, Journal Year: 2024, Volume and Issue: 32(1), P. 18 - 18

Published: Dec. 29, 2024

Background: While the clinical application of SII-ONCO-Bacillus Calmette–Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there a lack real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life safety SII-ONCO-BCG patients with intermediate- high-risk NMIBC. Methods: From January 2016 December 2023, medical records from six hospital centers were reviewed adult histologically confirmed stage Ta or T1 NMIBC (with without carcinoma situ [CIS]) who received at least one maintenance course after induction. Tumor recurrence progression monitored scheduled time intervals. Primary outcomes included recurrence-free survival (RFS) progression-free (PFS), while adverse events (AEs) constituted secondary outcomes. Results: A total 162 receiving enrolled. Among all patients, 145 (89.5%) men, 88 (54.3%) aged 70 years older, 103 (63.6%) had T1, 43 (26.5%) Ta, 21 (12.9%) concurrent CIS. The median follow-up duration was 28.9 months (range, 5–36) mean BCG intravesical instillation courses 13.7 9–27). After 3-, 2-, 1-year follow-up, RFS rates 85.2% (95% CI, 79.7–90.7%), 85.8% (80.4–91.2%), 87.0% (81.8–92.3%) observed, respectively. corresponding PFS 96.9% (94.2–99.6%), 97.5% (95.1–99.9%), During whole period, 24 (14.8%) experienced AE. Conclusions: demonstrates that an effective safe treatment

Language: Английский